Redeye takes a more positive stance on Teneo AI following the Q3 report showing accelerating SaaS AR...
Redeye comments on Sleep Cycle's Q3 2024 report, which showed a growth rate of 8.
Redeye see a Q3 report from Stille confirming continued organic growth and expanding margins, albeit...
Redeye comments on Polygiene Group´s third quarter of the year.
Redeye sees another quarter in which BONESUPPORT delivers well on sales (beating our US CERAMENT G s...
XVIVO delivers a Q3 that aligns with our expectations but is below market expectations due to FX hea...
Net sales SEK 170m, -9% vs ABGSCe, -10% vs Factset cons.
Redeye comments on SHH´s third quarter of the year.
Sales +4% vs. cons, adj. EBITA +20% vs. cons Minor positive consensus estimate revisions Awaiting im...
Sales -1% y-o-y, -3% vs. ABGSCe EBIT of SEK 63m, 75% vs.
Redeye retains its positive view of Carasent following a solid Q3 report showing accelerating organi...
Redeye initiates coverage of Neola Medical, a Swedish medtech company specialising in neonatal inten...
Redeye sees high uncertainty until the underlying market recovers.
Atria delivered a strong Q3, with adjusted EBIT 35% above LSEG Data & Analytics consensus.
'24e-'26e sales up 3-2% In line to reach annual growth target of ~50% Revised FVR of SEK 30-45 (25-4...
Catalyst to grow 94% in Q3'24e EBIT revised down by 1.
Sales -8% vs. ABGSCe (-11% y-o-y), adj. EBIT -7% vs.
Hyresintäkterna sjönk något till 847 mkr, främst drivet av tidigare avyttrade fastigheter.
Pharma Equity Group (“PEG” or “the Company”) announced on Wednesday, October the 23rd, that the Comp...
Q3 with healthy 7% organic growth despite headwinds Growth and cost improvement yields 300bp margin ...
